Active	Status	Sponsor type	Region	Phase	Filter
5 Active 0 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
McDowell, Carley
NCT05844423: Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Healthy Infants	Active, not recruiting	2	802	US	0.5 ml dose of 1.1 mcg VAX-24, 0.5 ml dose of PCV20, 0.5 ml dose of 2.2 mcg VAX-24, 0.5 ml dose of 2.2/4.4 mcg VAX-24	Vaxcyte, Inc.	Pneumococcal Vaccines	12/25	12/25
Mereddy, Swetha
NCT05156398 / 2021-005246-15: Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects	Recruiting	3	640	Europe, Canada, Japan, US	Rimegepant, BHV3000, Placebo, Matching Placebo	Pfizer, Biohaven Pharmaceuticals Holding Company Limited	Migraine	04/27	04/27
NCT06720038: A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy Infants	Recruiting	2	800	US	0.5 mL of the low dose VAX-31, 0.5 mL of the mid dose VAX-31, 0.5 mL of the high dose VAX-31, 0.5 mL dose of PCV20	Vaxcyte, Inc.	Pneumococcal Vaccines	06/27	06/27
NCT05844423: Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Healthy Infants	Active, not recruiting	2	802	US	0.5 ml dose of 1.1 mcg VAX-24, 0.5 ml dose of PCV20, 0.5 ml dose of 2.2 mcg VAX-24, 0.5 ml dose of 2.2/4.4 mcg VAX-24	Vaxcyte, Inc.	Pneumococcal Vaccines	12/25	12/25
Muniz-Pujalt, Gysella
NCT05844423: Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Healthy Infants	Active, not recruiting	2	802	US	0.5 ml dose of 1.1 mcg VAX-24, 0.5 ml dose of PCV20, 0.5 ml dose of 2.2 mcg VAX-24, 0.5 ml dose of 2.2/4.4 mcg VAX-24	Vaxcyte, Inc.	Pneumococcal Vaccines	12/25	12/25